Hosted on MSN1mon
Study finds GLP-1 receptor agonists target fat over muscle for weight loss
More information: Yiwen Liang et al, Relative effects of genetically proxied glucagon‐like peptide‐1 receptor agonism on muscle and fat mass: A Mendelian randomization study, Diabetes, Obesity ...
Weight loss drugs could help fight fatty liver disease
"This suggests that increasing glucagon will have additive beneficial effects to reduce liver fat, not only by reducing ...
Medscape9d
Short-term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes
Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...
The American Journal of Managed Care5d
GLP-1 RAs May Offer Broad Hepatic Benefits in MASH
Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...
Medscape8d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...